1,3-Benzodioxolyl-N-methylpentanamine

MBDP
Clinical data
Other names	MBDP; N-Methyl-1,3-benzodioxolylpentanamine; Methyl-K; UWA-091; UWA091; 3,4-Methylenedioxy-α-propyl-N-methyl-2-phenethylamine
Routes of; administration	Oral
ATC code	None;
Pharmacokinetic data
Duration of action	Unknown
Identifiers
	IUPAC name 1-(2H-1,3-benzodioxol-5-yl)-N-methylpentan-2-amine;
CAS Number	952016-78-3 ;
PubChem CID	17757316;
ChemSpider	21106348;
UNII	4D904VI4GR;
CompTox Dashboard (EPA)	DTXSID60590851 ;
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C2C(=CC=C1CC(NC)CCC)OCO2;
	InChI InChI=1S/C13H19NO2/c1-3-4-11(14-2)7-10-5-6-12-13(8-10)16-9-15-12/h5-6,8,11,14H,3-4,7,9H2,1-2H3; Key:PZVRSDBLMSXDCX-UHFFFAOYSA-N;

1,3-Benzodioxolyl-N-methylpentanamine (N-methyl-1,3-benzodioxolylpentanamine; MBDP; methyl-K, UWA-091), also known as 3,4-methylenedioxy-α-propyl-N-methylphenethylamine, is a psychoactive drug of the phenethylamine family.^[1]^[2]^[3] It is the N-methyl analogue of 1,3-benzodioxolylpentanamine (BDP; K). Methyl-K was first synthesized by Alexander Shulgin ("Sasha" Shulgin). In his book PiHKAL ("Phenethylamines i Have Known And Loved"), the minimum dosage is listed as 100 mg, and the duration is unknown.^[1] Very little is known about the pharmacology, pharmacokinetics, effects, and toxicity of Methyl-K.

Society and culture

^ ^a ^b ^c ^d "Methyl-K". PiHKAL.
^ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
^ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.